218 related articles for article (PubMed ID: 25275600)
1. Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling.
Dielschneider RF; Xiao W; Yoon JY; Noh E; Banerji V; Li H; Marshall AJ; Johnston JB; Gibson SB
Cell Death Dis; 2014 Oct; 5(10):e1439. PubMed ID: 25275600
[TBL] [Abstract][Full Text] [Related]
2. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
Feng G; Wang X
Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
[TBL] [Abstract][Full Text] [Related]
3. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.
Gobessi S; Laurenti L; Longo PG; Sica S; Leone G; Efremov DG
Blood; 2007 Mar; 109(5):2032-9. PubMed ID: 17038529
[TBL] [Abstract][Full Text] [Related]
4. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
[TBL] [Abstract][Full Text] [Related]
5. Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia.
Boelens J; Lust S; Van Bockstaele F; Van Gele M; Janssens A; Derycke L; Vanhoecke B; Philippé J; Bracke M; Offner F
Leuk Res; 2009 Oct; 33(10):1335-43. PubMed ID: 19297020
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.
Messmer D; Fecteau JF; O'Hayre M; Bharati IS; Handel TM; Kipps TJ
Blood; 2011 Jan; 117(3):882-9. PubMed ID: 21079155
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
8. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
9. Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia.
Wagner M; Oelsner M; Moore A; Götte F; Kuhn PH; Haferlach T; Fiegl M; Bogner C; Baxter EJ; Peschel C; Follows GA; Ringshausen I
Blood; 2016 Jan; 127(4):436-48. PubMed ID: 26508782
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
McCaig AM; Cosimo E; Leach MT; Michie AM
Br J Haematol; 2011 Apr; 153(2):199-211. PubMed ID: 21352196
[TBL] [Abstract][Full Text] [Related]
11. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.
Chen L; Widhopf G; Huynh L; Rassenti L; Rai KR; Weiss A; Kipps TJ
Blood; 2002 Dec; 100(13):4609-14. PubMed ID: 12393534
[TBL] [Abstract][Full Text] [Related]
12. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL).
Richardson SJ; Matthews C; Catherwood MA; Alexander HD; Carey BS; Farrugia J; Gardiner A; Mould S; Oscier D; Copplestone JA; Prentice AG
Blood; 2006 May; 107(9):3584-92. PubMed ID: 16332969
[TBL] [Abstract][Full Text] [Related]
13. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells.
Efremov DG; Gobessi S; Longo PG
Autoimmun Rev; 2007 Dec; 7(2):102-8. PubMed ID: 18035318
[TBL] [Abstract][Full Text] [Related]
14. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
Quiroga MP; Balakrishnan K; Kurtova AV; Sivina M; Keating MJ; Wierda WG; Gandhi V; Burger JA
Blood; 2009 Jul; 114(5):1029-37. PubMed ID: 19491390
[TBL] [Abstract][Full Text] [Related]
15. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
[TBL] [Abstract][Full Text] [Related]
17. The gene expression response of chronic lymphocytic leukemia cells to IL-4 is specific, depends on ZAP-70 status and is differentially affected by an NFκB inhibitor.
Ruiz-Lafuente N; Alcaraz-García MJ; Sebastián-Ruiz S; Gómez-Espuch J; Funes C; Moraleda JM; García-Garay MC; Montes-Barqueros N; Minguela A; Álvarez-López MR; Parrado A
PLoS One; 2014; 9(10):e109533. PubMed ID: 25280001
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ZAP-70/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia.
Laurenti L; Petlickovski A; Rumi C; Gobessi S; Piccioni P; Tarnani M; Puggioni P; Marietti S; Sica S; Leone G; Efremov DG
Haematologica; 2005 Nov; 90(11):1533-40. PubMed ID: 16266901
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia.
Cui B; Chen L; Zhang S; Mraz M; Fecteau JF; Yu J; Ghia EM; Zhang L; Bao L; Rassenti LZ; Messer K; Calin GA; Croce CM; Kipps TJ
Blood; 2014 Jul; 124(4):546-54. PubMed ID: 24914134
[TBL] [Abstract][Full Text] [Related]
20. The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients.
Colado A; Almejún MB; Podaza E; Risnik D; Stanganelli C; Elías EE; Dos Santos P; Slavutsky I; Fernández Grecco H; Cabrejo M; Bezares RF; Giordano M; Gamberale R; Borge M
Cancer Immunol Immunother; 2017 Apr; 66(4):461-473. PubMed ID: 28011996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
